Early Warning Report Filed Pursuant to National Instrument 62-103

(TheNewswire)

Glen Eagle Resources Inc. (the " Corporation ") (TSXV:GER) announces that it has disposed 163,500 common shares (each, a " Share ") of First Phosphate Corp. (" FPC ") throughout the period of April 25 to April 28, 2023 (the " Disposition "). Immediately after the Disposition, the Corporation has control and direction over an aggregate of 5,836,500 Shares representing 11.30 % of the issued and outstanding Shares of FPC

All securities of FPC controlled by Glen Eagle are held for investment purposes. In the future, it (directly or indirectly), may acquire and/or dispose of securities of FPC through the market, privately or otherwise, as circumstances or market conditions may warrant.

This press release is issued pursuant to the early warning requirements of National Instrument 62-104 – Take-Over Bids and Issuer Bids and National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues . A copy of the early warning report to be filed by Glen Eagle in connection with the Transaction will be available on the FPC's SEDAR profile once it has been filed in accordance with applicable securities laws and may be obtained by contacting:

ABOUT GLEN EAGLE RESOURCES INC.

Glen Eagle Resources Inc. is a small producer and an exploration company of precious metals in Canada and the central America area.

For more information, please contact:

Karl Trudeau
President
1-819-440-8495

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2023 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

TMO
The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News